These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23522120)

  • 1. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
    Zhang J; Shi Y; Lalonde E; Li L; Cavallone L; Ferenczy A; Gotlieb WH; Foulkes WD; Majewski J
    BMC Cancer; 2013 Mar; 13():146. PubMed ID: 23522120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
    Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
    BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    Li C; Bonazzoli E; Bellone S; Choi J; Dong W; Menderes G; Altwerger G; Han C; Manzano A; Bianchi A; Pettinella F; Manara P; Lopez S; Yadav G; Riccio F; Zammataro L; Zeybek B; Yang-Hartwich Y; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Zizioli V; Odicino F; Pecorelli S; Ardighieri L; Silasi DA; Litkouhi B; Ratner E; Azodi M; Huang GS; Schwartz PE; Lifton RP; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):619-624. PubMed ID: 30584090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
    J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
    J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
    J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
    Badora A; Kaleta B; Nowara E; Sikora-Jopek M; Budryk M; Smok-Ragankiewicz A
    Ginekol Pol; 2013 Oct; 84(10):892-6. PubMed ID: 24273914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
    Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
    Sokolenko AP; Bizin IV; Preobrazhenskaya EV; Gorodnova TV; Ivantsov AO; Iyevleva AG; Savonevich EL; Kotiv KB; Kuligina ES; Imyanitov EN
    Int J Cancer; 2020 Apr; 146(7):1879-1888. PubMed ID: 31693165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
    Tworek H; Peng R; Fetzer S; Werness BA; Piver MS; Allen HJ; DiCioccio RA
    Cancer Genet Cytogenet; 1999 Jul; 112(2):105-18. PubMed ID: 10686936
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of BRCA1 and BRCA2 in ovarian cancer.
    Hilton JL; Geisler JP; Rathe JA; Hattermann-Zogg MA; DeYoung B; Buller RE
    J Natl Cancer Inst; 2002 Sep; 94(18):1396-406. PubMed ID: 12237285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.